Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLG | P00747 | 1/20 | 0.46 |
| ▸ | PLAT | P00750 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | S1PR5 | Q9H228 | 7/20 | 0.41 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.39 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 6/20 | 0.38 |
| ▸ | ANPEP | P15144 | 1/20 | 0.38 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | S1PR3 | Q99500 | 4/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14932056 | 0.83 | PLG (0.50) | PLGPLATLMNASMN1; SMN2CYP4F2 | |
| SCHEMBL17592437 | 0.83 | PLG (0.50) | PLGPLATLMNASMN1; SMN2CYP4F2 | |
| SCHEMBL849225 | 0.83 | PLG (0.50) | PLGPLATLMNASMN1; SMN2CYP4F2 | |
| SCHEMBL14658202 | 0.82 | SMN1; SMN2 (0.58) | SMN1; SMN2ALDH1A1TDP1 | |
| SCHEMBL125382 | 0.82 | — | — | |
| SCHEMBL11954680 | 0.82 | MAPT (0.39) | LMNASMN1; SMN2ALDH1A1TDP1 | |
| SCHEMBL14390048 | 0.82 | MAPT (0.39) | LMNASMN1; SMN2ALDH1A1TDP1 | |
| SCHEMBL25960460 | 0.82 | PLG (0.46) | PLGPLATLMNACYP4F2CYP4A11 | |
| SCHEMBL15026691 | 0.81 | CYP3A4 (0.50) | PLGPLATLMNAS1PR5CYP4F2 | |
| SCHEMBL13107064 | 0.78 | SMN1; SMN2 (0.54) | SMN1; SMN2ALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11707457-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11707457-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | PLG 1441/4885PLAT 1236/4885LMNA 1656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.